cadazolid

01/01/2019 - "Therefore, further commercial development of cadazolid for C difficile infection is unlikely. "
01/01/2019 - "We aimed to investigate the safety and efficacy of cadazolid compared with vancomycin in patients with C difficile infection. "
01/01/2019 - "Cadazolid was safe and well tolerated but did not achieve its primary endpoint of non-inferiority to vancomycin for clinical cure in one of two phase 3 C difficile infection trials. "
01/01/2019 - "Cadazolid is the first member of quinoxolidinone antibiotics, which are characterized by combining the pharmacophores of oxazolidinones and fluoroquinolones, and it is evaluated for treatment of Clostridium difficile gastrointestinal infections that frequently occur in hospitalized patients. "

01/01/2019 - "Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials."
11/01/2015 - "Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection."
01/01/2015 - "Cadazolid: A new hope in the treatment of Clostridium difficile infection."
10/01/2015 - "Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection."
01/01/2020 - "Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis."

04/01/2017 - "Expert opinion: Preclinical and early clinical studies demonstrated that cadazolid has unique properties that will likely be valuable to treat CDI and reduce recurrent infection. "
04/01/2013 - "In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden."

10/01/2015 - "The times to diarrhea resolution were similar for cadazolid and vancomycin. "
01/01/2014 - "In the hamster and mouse models for CDAD, cadazolid was active, conferring full protection from diarrhea and death with a potency similar to that of vancomycin. "
01/01/2021 - "However, cadazolid (CZD) and vancomycin (VAN) showed less protection of infected mice than did OBP-4 in terms of diarrhea and weight loss, especially VAN. "
01/01/2014 - "Cadazolid is a new oxazolidinone-type antibiotic currently in clinical development for the treatment of Clostridium difficile-associated diarrhea. "

01/01/2021 - "However, cadazolid (CZD) and vancomycin (VAN) showed less protection of infected mice than did OBP-4 in terms of diarrhea and weight loss, especially VAN. "